The US laboratory Johnson & Johnson recorded a net profit of 6,197 million dollars (5,139 million euros) in the first three months of 2021, which represents an increase of 6.9% with respect to the profits corresponding to the same period of the year. previous year, according to the annual accounts published by the multinational.
The company’s revenues between January and March stood at 22,321 million dollars (18,511 million euros), which represents an increase of 7.9% compared to the first quarter of 2020.
The pharmaceutical products division had a turnover of 9.6% more, up to 12,199 million dollars (10,117 million euros), while the income from the sale of medical devices increased 10.9%, up to 6,579 million dollars (5,456 millions of euros). The branch of non-prescription drugs, hygiene products and skin care received 3,543 million dollars (2,938 million euros), 2.3% less.
Likewise, the multinational specified that in the first three months of the year its sales in the United States increased by 3.9% year-on-year, to 11,111 million dollars (9,215 million euros). On its side, Johnson & Johnson’s international turnover grew by 12.2%, to 11,210 million dollars (9,297 million euros).
On the other hand, the company’s board of directors has declared a 5% increase in the quarterly dividend, which will be $ 1.06 per share and will be paid on June 8. In this way, the annual compensation would reach 4.24 dollars per share, compared to 4.04 dollars the previous year.
“Despite an unprecedented difficult year, Johnson & Johnson remained committed to its financial principles that strengthen our ability to create long-term value for stakeholders,” said Alex Gorsky, president and CEO of the company.
